Edwards Lifesciences
Edwards LifesciencesEdwards Lifesciences has acquired a few companies in the transcatheter mitral valve repair space. The company acquired privately-held CardiAQ Valve Technologies in July 2015 for $400 million with $350 million in cash at closing.
CardiAQ Valve Technologies received FDA approval in April 2015 for an early feasibility trial of its second generation transcatheter mitral valve implant.
The company says it is looking to achieve “a number of meaningful clinical milestones” this year in the transcatheter mitral replacement arena.
